Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function - PubMed (original) (raw)
Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function
Noriko Oshiro et al. Genes Cells. 2004 Apr.
Free article
Erratum in
- Genes Cells. 2004 May;9(5):497
Abstract
The mammalian target of rapamycin (mTOR) is a Ser/Thr protein kinase that plays a crucial role in a nutrient-sensitive signalling pathway that regulates cell growth. TOR signalling is potently inhibited by rapamycin, through the direct binding of a FK506-binding protein 12 (FKBP12)/rapamycin complex to the TOR FRB domain, a segment amino terminal to the kinase catalytic domain. The molecular basis for the inhibitory action of FKBP12/rapamycin remains uncertain. Raptor (regulatory associated protein of mTOR) is a recently identified mTOR binding partner that is essential for mTOR signalling in vivo, and whose binding to mTOR is critical for mTOR-catalysed substrate phosphorylation in vitro. Here we investigated the stability of endogenous mTOR/raptor complex in response to rapamycin in vivo, and to the direct addition of a FKBP12/rapamycin complex in vitro. Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity. Rapamycin, in the presence of FKBP12, inhibited the association of raptor with mTOR directly in vitro, and concomitantly reduced the mTOR-catalysed phosphorylation of raptor-dependent, but not raptor-independent substrates; mTOR autophosphorylation was unaltered. These observations indicate that rapamycin inhibits mTOR function, at least in part, by inhibiting the interaction of raptor with mTOR; this action uncouples mTOR from its substrates, and inhibits mTOR signalling without altering mTOR's intrinsic catalytic activity.
Similar articles
- A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K. Shor B, et al. Cancer Res. 2008 Apr 15;68(8):2934-43. doi: 10.1158/0008-5472.CAN-07-6487. Cancer Res. 2008. PMID: 18413763 - The FRB domain of mTOR: NMR solution structure and inhibitor design.
Leone M, Crowell KJ, Chen J, Jung D, Chiang GG, Sareth S, Abraham RT, Pellecchia M. Leone M, et al. Biochemistry. 2006 Aug 29;45(34):10294-302. doi: 10.1021/bi060976+. Biochemistry. 2006. PMID: 16922504 - Rheb binds and regulates the mTOR kinase.
Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Long X, et al. Curr Biol. 2005 Apr 26;15(8):702-13. doi: 10.1016/j.cub.2005.02.053. Curr Biol. 2005. PMID: 15854902 - The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M, Rowinsky EK. Hidalgo M, et al. Oncogene. 2000 Dec 27;19(56):6680-6. doi: 10.1038/sj.onc.1204091. Oncogene. 2000. PMID: 11426655 Review. - Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K. Avruch J, et al. Oncogene. 2006 Oct 16;25(48):6361-72. doi: 10.1038/sj.onc.1209882. Oncogene. 2006. PMID: 17041622 Review.
Cited by
- Emerging molecular therapies in the treatment of bladder cancer.
Bell SD, Quinn AE, Spitzer TD, Voss BB, Wakefield MR, Fang Y. Bell SD, et al. Explor Target Antitumor Ther. 2024;5(5):1135-1154. doi: 10.37349/etat.2024.00267. Epub 2024 Aug 29. Explor Target Antitumor Ther. 2024. PMID: 39351439 Free PMC article. Review. - Fer governs mTORC1 regulating pathways and sustains viability of pancreatic ductal adenocarcinoma cells.
Schrier I, Slotki-Itzchakov O, Elkis Y, Most-Menachem N, Adato O, Fitoussi-Allouche D, Shpungin S, Unger R, Nir U. Schrier I, et al. Front Oncol. 2024 Aug 14;14:1427029. doi: 10.3389/fonc.2024.1427029. eCollection 2024. Front Oncol. 2024. PMID: 39206154 Free PMC article. - Identification and characterization of TOR in Macrobrachium rosenbergii and its role in muscle protein and lipid production.
Dai X, Li X, Yin D, Chen X, Wang L, Pang L, Fu Y. Dai X, et al. Sci Rep. 2024 Jan 24;14(1):2082. doi: 10.1038/s41598-023-50300-3. Sci Rep. 2024. PMID: 38267514 Free PMC article. - Silibinin Downregulates Types I and III Collagen Expression via Suppression of the mTOR Signaling Pathway.
Choi S, Ham S, Lee YI, Kim J, Lee WJ, Lee JH. Choi S, et al. Int J Mol Sci. 2023 Sep 21;24(18):14386. doi: 10.3390/ijms241814386. Int J Mol Sci. 2023. PMID: 37762688 Free PMC article. - Inhibition of phosphodiesterase 4D suppresses mTORC1 signaling and pancreatic cancer growth.
Jeong MH, Urquhart G, Lewis C, Chi Z, Jewell JL. Jeong MH, et al. JCI Insight. 2023 Jul 10;8(13):e158098. doi: 10.1172/jci.insight.158098. JCI Insight. 2023. PMID: 37427586 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous